01561nam--2200433---450-99000222481020331620100903123740.088-495-0842-5000222481USA01000222481(ALEPH)000222481USA0100022248120041129d2004----km-y0enga50------baitaITy---z---001yy<<Gli>> enti religiosi nella trasformazione dello stato socialeMarco ParisiNapoliEdizioni Scientifiche Italianecopyr. 2004226 p.24 cmUniversità degli studi del Molise, Dipartimento di scienze giuridico-sociali e dell'amministrazione192001Università degli studi del Molise, Dipartimento di scienze giuridico-sociali e dell'amministrazione192001001------2001Cristianesimo e societaEnti senza scopo di lucro261.832PARISI,Marco329590ITsalbcISBD990002224810203316XXX.A. Coll. 148/ 17 (X 46 III 19)45451 G.XXX.A. Coll. 148/ 17 (X 46 III)00116185BKGIUMARIA1020041129USA011140IANNONE9020050627USA011433IANNONE9020050719USA011420RSIAV29020100903USA011237CHIARA9020110301USA011439Enti religiosi nella trasformazione dello stato sociale1035612UNISA04840nam 22009253u 450 991014639730332120231129014806.01-280-30974-197866103097401-84692-556-8(CKB)1000000000463450(EBL)362703(OCoLC)476194143(SSID)ssj0000258330(PQKBManifestationID)12112418(PQKBTitleCode)TC0000258330(PQKBWorkID)10257141(PQKB)10109792(EXLCZ)99100000000046345020130418d2005|||| u|| |engur|n|---|||||txtccrTherapeutic Strategies in Lymphoid Malignancies[electronic resource] An Immunotherapeutic ApproachOxford Atlas Medical Publishing Ltd20051 online resource (238 p.)Therapeutic StrategiesDescription based upon print version of record.1-904392-52-0 Contents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; IndexTargeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drugTherapeutic StrategiesCancerLymphaticsLymphomaLymphomaImmunotherapyLymphoproliferative DisordersNeoplasms by Histologic TypeImmunomodulationLymphatic DiseasesBiological TherapyImmunoproliferative DisordersNeoplasmsImmune System DiseasesDiseaseTherapeuticsHemic and Lymphatic DiseasesDiagnostic Techniques and ProceduresCancer.Lymphatics.Lymphoma.Lymphoma.Immunotherapy.Lymphoproliferative Disorders.Neoplasms by Histologic Type.Immunomodulation.Lymphatic Diseases.Biological Therapy.Immunoproliferative Disorders.Neoplasms.Immune System Diseases.Disease.Therapeutics.Hemic and Lymphatic Diseases.Diagnostic Techniques and Procedures.616.994420637Hillmen P1001216Witzig TE1001217AU-PeELAU-PeELAU-PeELBOOK9910146397303321Therapeutic Strategies in Lymphoid Malignancies2298040UNINA04739nam 22005775 450 991033756540332120251116212053.03-030-03035-010.1007/978-3-030-03035-3(CKB)4100000007758134(MiAaPQ)EBC5723054(DE-He213)978-3-030-03035-3(PPN)235233870(EXLCZ)99410000000775813420190305d2019 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierArchitecture for Blockchain Applications /by Xiwei Xu, Ingo Weber, Mark Staples1st ed. 2019.Cham :Springer International Publishing :Imprint: Springer,2019.1 online resource (312 pages)3-030-03034-2 1 Introduction -- 2 Existing Blockchain Platforms -- 3 Varieties of Blockchains -- 4 Example Use Cases -- 5 Blockchain in Software Architecture -- 6 Design Process for Applications on Blockchain -- 7 Blockchain Patterns -- 8 Model-driven Engineering for Applications on Blockchains -- 9 Cost -- 10 Performance -- 11 Dependability and Security -- 12 Case Study: AgriDigital -- 13 Case Study: SecureVote -- 14 Case Study: originChain -- Epilogue -- References -- Index.This book addresses what software architects and developers need to know in order to build applications based on blockchain technology, by offering an architectural view of software systems that make beneficial use of blockchains. It provides guidance on assessing the suitability of blockchain, on the roles blockchain can play in an architecture, on designing blockchain applications, and on assessing different architecture designs and tradeoffs. It also serves as a reference on blockchain design patterns and design analysis, and refers to practical examples of blockchain-based applications. The book is divided into four parts: Part I provides a general introduction to the topic and to existing blockchain platforms including Bitcoin, Ethereum, and Hyperledger Fabric, and offers examples of blockchain-based applications. Part II focuses on the functional aspects of software architecture, describing the main roles blockchain can play in an architecture, as well as its potential suitability and design process. It includes a catalogue of 15 design patterns and details how to use model-driven engineering to build blockchain-based applications. Part III covers the non-functional aspects of blockchain applications, which are cross-cutting concerns including cost, performance, security, and availability. Part IV then presents three detailed real-world use cases, offering additional insights from a practical perspective. An epilogue summarizes the book and speculates on the role blockchain and its applications can play in the future. This book focusses on the bigger picture for blockchain, covering the concepts and technical considerations in the design of blockchain-based applications. The use of mathematical formulas is limited to where they are critical. This book is primarily intended for developers, software architects and chief information officers who need to understand the basic technology, tools and methodologies to build blockchain applications. It also provides students and researchers new to this field an introduction to this hot topic.Software engineeringApplication softwareComputer securityData protectionSoftware Engineeringhttps://scigraph.springernature.com/ontologies/product-market-codes/I14029Information Systems Applications (incl. Internet)https://scigraph.springernature.com/ontologies/product-market-codes/I18040Systems and Data Securityhttps://scigraph.springernature.com/ontologies/product-market-codes/I28060Securityhttps://scigraph.springernature.com/ontologies/product-market-codes/I28000Software engineering.Application software.Computer security.Data protection.Software Engineering.Information Systems Applications (incl. Internet).Systems and Data Security.Security.005.74Xu Xiweiauthttp://id.loc.gov/vocabulary/relators/aut1057959Weber Ingoauthttp://id.loc.gov/vocabulary/relators/autStaples Markauthttp://id.loc.gov/vocabulary/relators/autBOOK9910337565403321Architecture for Blockchain Applications2495894UNINA